Cenegermin
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor. Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR). The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye. It was approved for medical use in the European Union in July 2017, and in the United States in 2018. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor. Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR). The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye. It was approved for medical use in the European Union in July 2017, and in the United States in 2018. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1345276926 under CC BY-SA 4.0; modifications have been made.